Related Experiment Video
Updated: Jun 7, 2025
06:27
A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
246
Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase-mutant lower-grade gliomas
Dongxu Zhao1, Lin Duan1, Tareq A Juratli2
1Department of Cerebrovascular Disease and Neurosurgery, Henan University People's Hospital, Henan Provincial People's Hospital, Zhengzhou, 450003, China.
Annals of Clinical and Translational Neurology
|November 18, 2024
Summary
A new nomogram model accurately predicts glioma grade and IDH mutation status using imaging and molecular features. This non-invasive tool aids clinical decisions for better patient management in diffuse glioma.
Area of Science:
- Neuro-oncology
- Radiology
- Molecular Diagnostics
Background:
- Glioma grading and isocitrate dehydrogenase (IDH) mutation status are critical for patient prognosis and treatment.
- Accurate non-invasive methods are needed to differentiate glioma grades and determine IDH mutation status.
Purpose of the Study:
- To develop and validate a predictive model for glioma grading and IDH mutation status.
- To assess the efficacy of imaging features and magnetic resonance spectroscopy (MRS) in differentiating glioma subtypes.
Main Methods:
- Retrospective analysis of 383 adult diffuse glioma patients across two institutions.
- Construction of a nomogram model using stepwise regression based on clinical and radiographic features.
- Evaluation of Hyper fluid-attenuated inversion recovery (FLAIR) rim sign, T2-FLAIR mismatch sign, and MRS indicators (Cho/Cr ratio).
Main Results:
- The T2-FLAIR mismatch sign showed better clinical efficacy than the Hyper FLAIR rim sign for predicting glioma grade and IDH mutation status.
- Preoperative MRS indicators, particularly the Cho/Cr ratio, demonstrated excellent performance.
- The developed nomogram exhibited excellent predictive capabilities for glioma grading and IDH mutation status.
Conclusions:
- A combined imaging and molecular predictive model offers a reliable non-invasive tool for glioma grading and IDH mutation status determination.
- This model can aid clinical decision-making and improve patient management strategies for diffuse gliomas.
